Zobrazeno 1 - 10 of 81 pro vyhledávání: '"E Santacana"'
1
Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness
Autor: Xose L. Perez-Fernandez, Virginia Esteve, Pau Cerdà, Antoni Sabate, Sergi Yun, Ferran Bolao, Jose Maria Mora, Maria Quero, Josep Comin-Colet, Elisabet Leiva, E Santacana, A. Riera-Mestre, Albert Ariza-Solé, Guillermo Suarez-Cuartin, Mar Ronda, Merce Gasa, Mariona Llaberia, Ariadna Padullés, Jordi Guardiola, Carlos García-Forero, Francesc Formiga, Salud Santos, F. Mitjavila, Joan Sabater, Adriana Iriarte, Xavier Corbella, Alberto Pasqualetto, Abelardo Montero, Olga Capdevila, Marta Fanlo, Josep M. Cruzado, Josep Llop, Xavier Solanich, Paolo Dallaglio, Manuel Rubio-Rivas, Rafael Moreno-Gonzalez, Monica Gonzalez, David Chivite, Maylin Koo, Ramon Jodar, N Padullés, Xavier Pintó, Antonio Soriano, Arnau Antolí
Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
International Journal of Infectious Diseases, Vol 101, Iss, Pp 290-297 (2020)
International Journal of Infectious Diseases
Highlights • Dexamethasone, or alternative steroids, are recommended in severe COVID-19. • The use of tocilizumab in COVID-19, with or without steroids, is still controversial. • Risk for mortality was assessed in 186 COVID-19 patients receivin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6079fd35ce0e0a4471ef552b2a664ef2
https://doi.org/10.1101/2020.08.31.20182428
Zobrazit plný text záznamu
2
External Evaluation of Population Pharmacokinetic Models of Infliximab in Patients With Inflammatory Bowel Disease
Autor: E Santacana, N Padullés, Helena Colom, J Bas, Jordi Guardiola, Lorena Rodríguez-Alonso, Ariadna Padullés, Katja Serra, Francisco Rodríguez-Moranta, Francisco Morandeira Biology
Publikováno v: Therapeutic Drug Monitoring. 40:120-129
Background Infliximab (IFX) trough levels vary markedly between patients with inflammatory bowel disease (IBD), which is important for clinical response. The aim of this study was to evaluate the performance of previously developed population pharmac
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::633c2b86ee2e8adf1919ee975be49a8c
https://doi.org/10.1097/ftd.0000000000000476
Zobrazit plný text záznamu
3
P264 Impact of the HLA-DQ1*05 alelle on the initial response to infliximab in patients with Inflammatory Bowel Disease
Autor: Francisco Rodríguez-Moranta, Lorena Rodríguez-Alonso, K Serra, A. Ruiz, C Arajol, Jordi Guardiola, N Padullés, Eduardo Sánchez, A Padró, R Blat, Ana Berrozpe, E Santacana, G. Suris Marin
Publikováno v: Journal of Crohn's and Colitis. 15:S301-S302
Background HLA-DQA1*05 Carriage is associated with development of anti-drug antibodies to infliximab in patients With Crohn’s Disease (Sazonovs et al. Gastroenterology 2019). Our group has shown that the presence of this allele is also an independe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c7ba0543dd3f9fa25b8e7c5697fbfbe0
https://doi.org/10.1093/ecco-jcc/jjab076.390
Zobrazit plný text záznamu
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design
Autor: J Bas, Ariadna Padullés, E Santacana, Katja Serra, Jordi Guardiola, Lorena Rodríguez-Alonso, Francisco Rodríguez-Moranta, Francisco Morandeira, Helena Colom, N Padullés
Publikováno v: Therapeutic drug monitoring. 42(1)
Background and aims Treating patients based on a treat-to-trough approach has been shown to be a cost-effective strategy for inflammatory bowel disease (IBD) patients who have become unresponsive to infliximab (IFX). However, the documented evidence
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf6f8f330d1dcd81bfd4c91383092f83
https://pubmed.ncbi.nlm.nih.gov/31283556
Zobrazit plný text záznamu
6
P711 Carriage of the HLA-DQA1*05 allele is associated with a high risk of loss of response to adalimumab in patients with Crohn’s disease
Autor: J Guardiola Capón, A Padró, Francisco Rodríguez-Moranta, N Padullés, K Serra, Blau Camps, J Orobitg, E Santacana, C Arajol, Alexandra Ruiz-Cerulla, G Surís, Lorena Rodríguez-Alonso
Publikováno v: Journal of Crohn's and Colitis. 14:S574-S574
Background Loss of response (LOR) to tumour necrosis factor antagonists (anti-TNF) occurs in up to 50% of patients with inflammatory bowel disease (IBD). The ability to predict which patients are likely to lose response would allow therapies to be ta
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2bd1af9ab2f6ce90c4f94e0a646a8ff8
https://doi.org/10.1093/ecco-jcc/jjz203.839
Zobrazit plný text záznamu
7
6ER-001 Association between faecal calprotectin values and infliximab trough levels in inflammatory bowel disease patients
Autor: J Bas, N Padullés, Ariadna Padullés, Lorena Rodríguez-Alonso, Jordi Guardiola, CM Esteban-Sánchez, E Santacana, Helena Colom
Publikováno v: Europe PubMed Central
Eur J Hosp Pharm
BACKGROUND: Serum infliximab (IFX) trough levels (Cmin) have been associated with clinical response. Therapeutic drug monitoring of IFX has been shown to be clinical and cost effective in inflammatory bowel disease (IBD) patients. However, some patie
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a9d1c03b180cd24ecf4fb586f9751f6
https://doi.org/10.1136/ejhpharm-2018-eahpconf.494
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje